Ospemifene Improves Vaginal Microbiome In Postmenopausal Women With Vulvovaginal Atrophy
- byDoctor News Daily Team
- 10 July, 2025
- 0 Comments
- 0 Mins
Italy: An original study entitled "Effect of ospemifene on the vaginal microbiome in postmenopausal women with vulvovaginal atrophy" has stated that "Ospemifene" is beneficial for postmenopausal women in maintaining vaginal health by reducing the number of "potentially harmful" bacteria.
The study findings are published in Menopause, The Journal of the North American Menopause Society.
Researchers compared the vaginal microbiome profile of women with vulvovaginal atrophy to healthy postmenopausal women.
The team also assessed, “What are the effectiveness of Ospemifene and systemic hormone treatment on vaginal microbiome composition?”
The study summary includes the following:
The researchers enrolled 67 postmenopausal women attending the Gynecology Clinic of Azienda Ospedaliero-Universitaria of Bologna (Italy).
Thirty-nine women were diagnosed with atrophy, and 28 were healthy.
In the atrophic women group, 20 received ospemifene and 19 hormone treatment.
16S rRNA gene sequencing was used to analyse the vaginal microbiome.
After three months of treatment, Clinical/microbiological analyses were repeated.
Among atrophic women, there was a significantly reduced number of lactobacillus and increased Streptococcus and Sneathia.
A positive correlation was recorded between vaginal health index/vaginal maturation index and Lactobacillus abundance.
Both treatment approaches effectively improved vaginal indices.
In the women on Systemic hormone treatment, there were changes induced in the minority bacterial groups.
Among women on ospemifene, specific bacterial taxa, like Staphylococcus and Clostridium, were eliminated.
Bifidobacteria increased with both treatments.
To conclude, there is a significant difference between the vaginal microbiome of atrophic women and healthy postmenopausal women. Ospemifene reduces harmful bacteria and promotes good vaginal health.
Further reading:
Alvisi, Stefania MD1,2; Ceccarani, Camilla PhD3; Foschi, Claudio MD4,5; Baldassarre, Maurizio PhD2,6; Lami, Alessandra MD1,2; Severgnini, Marco MSc3; Camboni, Tania PhD3; Consolandi, Clarissa PhD3; Seracchioli, Renato MD1,2; Meriggiola, Maria Cristina MD, PhD1,2. Effect of ospemifene on the vaginal microbiome in postmenopausal women with vulvovaginal atrophy. Menopause ():10.1097/GME.0000000000002150, January 24, 2023. | DOI: 10.1097/GME.0000000000002150
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Eli Lilly plans to build new USD 3 billion facilit...
- 04 November, 2025
Rajkot Maternity Hospital CCTV Leak: How a simple...
- 04 November, 2025
Gland Pharma profit rises 12 percent to Rs 184 cro...
- 04 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!